<DOC>
	<DOC>NCT00099554</DOC>
	<brief_summary>The purpose of this study is to evaluate the proportion of Rheumatoid Arthritis (RA) subjects achieving a "good" or "moderate" DAS28 response (EULAR28 criteria) at Week 16 with etanercept 50 mg subcutaneously (SC) once weekly in patients who have failed infliximab.</brief_summary>
	<brief_title>Effectiveness and Safety of Enbrel® (Etanercept) in Rheumatoid Arthritis Subjects Who Have Failed Remicade® (Infliximab)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Adults with RA (ACR criteria) for greater than or equal to 6 months Infliximab treatment for at least 18 weeks Infliximab infusion prior to screening at an increased dosing regimen: 5 mg/kg every 48 weeks (dose), OR, 3 mg/kg every 46 weeks (frequency) Failing infliximab defined by ALL of the following at screening and baseline visit: Disease Activity Score (DAS 28) greater than or equal to 4.5, greater than or equal to 5 swollen joints, greater than or equal to 5 tender joints Subjects must be receiving stable methotrexate (MTX), at a dose of greater than or equal to 10 mg/week at least 10 weeks prior to screening Stable disease modifying antirheumatic drugs (DMARD) therapy (including sulfasalazine, hydroxychloroquine), greater than or equal to 8 weeks prior to screening Stable dose corticosteroids, less than 10 mg/day at greater than or equal to 4 weeks prior to screening Stable dose of nonsteroidal antiinflammatory drugs (NSAIDs) greater than or equal to 1 week prior to screening ACR functional class IV Prior treatment with etanercept Receipt of any investigational drug/biologic within 28 days of study drug initiation Active infection or predisposition to infection Elective surgery planned during study period Intraarticular, soft tissue, or intramuscular corticosteroid injections during 4 weeks prior to screening Contraindications to etanercept as defined in the package insert Severe comorbidities: History of cancer within 5 years; Diagnosis of class III or IV congestive heart failure (CHF); Uncontrolled hypertension (HTN); CNSdemyelinating events suggestive of multiple sclerosis (MS); Known HIVpositive status; Oxygendependent pulmonary status; Chronic hepatitis B or C; Systemic Lupus Erythematosus (SLE); Active or prior history of tuberculosis (TB) (or known exposure) or positive PPD without adequate TB prophylaxis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>